Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6436 to 6450 of 7707 results

  1. Laparoscopic radical hysterectomy for early stage cervical cancer (IPG338)

    This guidance has been updated and replaced by NICE interventional procedures guidance 686.

  2. Low-intensity pulsed ultrasound to promote fracture healing (IPG374)

    This guidance has been updated and replaced by:

  3. External aortic root support in Marfan syndrome (IPG394)

    This guidance has been updated and replaced by NICE interventional procedures guidance 724.

  4. Off-pump coronary artery bypass (OPCAB) (IPG35)

    This guidance has been updated and replaced by NICE interventional procedure guidance 377.

  5. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG343)

    This guidance has been updated and replaced by NICE interventional procedure guidance 494.

  6. Health app: ChatHealth communication platform in school nursing services (MIB130)

    The health app briefing on ChatHealth communication platform in school nursing services has been withdrawn.

  7. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  8. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued [GID-MT516]

  9. Abicipar pegol for treating wet age-related macular degeneration ID1533

    In development [GID-TA10511] Expected publication date: TBC

  10. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued [GID-TA10394]

  11. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued [GID-TA11119]

  12. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

  13. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]